Oxygen Biotherapeutics Now Covered by Analysts at Ladenburg Thalmann (OXBT)
Equities researchers at Ladenburg Thalmann began coverage on shares of Oxygen Biotherapeutics (NASDAQ:OXBT) in a research report issued on Monday, TheFlyOnTheWall.com reports. The firm set a “buy” rating on the stock.
Shares of Oxygen Biotherapeutics (NASDAQ:OXBT) traded down 8.84% on Monday, hitting $6.70. The stock had a trading volume of 7,953,788 shares. Oxygen Biotherapeutics has a 52 week low of $1.19 and a 52 week high of $22.00. The stock has a 50-day moving average of $1.53 and a 200-day moving average of $3.58. The company’s market cap is $71.2 million.
Oxygen Biotherapeutics, Inc (NASDAQ:OXBT) is engaged in the business of developing biotechnology products with a focus on oxygen delivery to tissue.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.